Transparency Market Research Epigenetics Drugs and Diagnostic Technologies Market is growing at a CAGR of 19.4% from 2013 to 2019. By Transparency Market Research.
Single User License:
USD 4595 Multi User License:
USD 7595 Corporate User License:
USD 10595
Published Date 26-June-2013
112 Page Report
Request Sample
Buy Now
Press Release
Epigenetics Drugs and Diagnostic Technologies Market is Expected to Reach USD 5.7 Billion Globally in 2018: Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Epigenetics Drugs and Diagnostic Technologies Market
REPORT DESCRIPTION
Epigenetics Drugs and Diagnostic Technologies Market was valued at USD 1.6 billion in 2013 and is estimated to reach a market worth USD 5.7 billion in 2019 at a CAGR of 19.4% from 2013 to 2019.
Browse the full report at http://www.transparencymarketresearch.com/epigeneticsmarket.html The growth of the epigenetics market is driven by factors such as increase in aging population, as there is a strong correlation between cancer and aging. According to WHO, it is estimated that global population over the age of 60 years would double from 11% (2000) to 22% (2050). People aged 60 and above are more prone to cancer. Hence, countries are advocating early detection of cancer through screening kits (Epi Procolon, Epi ProLung) which are driving the epigenetic drugs and diagnostic technologies market.
Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. The inhibitors, DNA methyltransferase (DNMT) and Histone Deacetylase (HDAC) are responsible for regulating the cellular expression. Out of the two inhibitors, DNMT accounts for a larger share as these inhibitors offer an improved access for targeting the cancerous cells. Currently, four drugs are approved by FDA and are commercially available. Two of them are DNMT inhibitors: Celgene's Vidaza (azacitidine) and Eisai's Dacogen (decitabine) for the treatment of Myelodysplastic Syndrome (MDS), and the other two are HDAC inhibitors: Merck's Zolinza (vorinostat) and Celgene's Istodax (romidepsin) both for treatment of Cutaneous T Cell Lymphoma (CTCL). Epigenetics is a rapidly developing field not only in oncology but also in non-oncology indications (Alzheimer's and arthritis). Due to the increase in disease identification, manufacturers are taking initiatives in development of varied epigenetic diagnostic techniques. DNA methylation technique in the diagnostic segment accounts for the largest share as compared to histone modification techniques, as the research on DNA methylation has been carried out since decades, and is thus mostly preferred. Furthermore, with the corresponding advancements in research and technology, histone code hypothesis technique came into existence only in late
Transparency Market Research
2
Epigenetics Drugs and Diagnostic Technologies Market
1980s. Hence, with the surge in interest, there is also an increase in investment for the research and development of histone modifications. North America accounts for the largest share of the epigenetics market. It is expected that North America will dominate around half of the global epigenetics market due to increasing incidence of cancer and other non-oncology indications. Oncology and other non-oncology indications (Alzheimer's and arthritis) are associated with epigenetics; thus the increasing incidence of cancer supports the growth of the epigenetics market. Asia accounts for nearly half of the new cancer cases worldwide. The rising incidence of cancer cases in the Asian region would boost the demand for epigenetic drugs and diagnostic technologies in this market. Australia, China, Japan and South Korea are the largest markets for these therapies. Japan dominates the epigenetics market in Asia-Pacific due to a significant presence of companies in the therapeutics segment such as Eisai Pharmaceuticals and Oncolys Biopharma. These companies are taking initiatives for the development and commercialization of epigenetic drugs. Various research institutes and investments from these companies would drive the epigenetics market. Some of the key players in this market include Celgene Corporation, Merck, Eisai Pharmaceuticals, Exact Sciences, Epigenomics and others. Manufacturers are entering into strategic alliances with numerous research institutions and other players for the development and commercialization of new and innovative drugs, which might see new players in the market looking to carve out a share of the market for themselves. The epigenetics drugs and diagnostic technologies market is segmented as follows: Epigenetics Drugs Market, by Mechanism of Action DNMT Inhibitors Epigenetics Diagnostic Technologies Market, by Types DNA Methylation Chromatin Immunoprecipitation (ChIP) Technology Epigenetics Technologies Market, by Geography North America Europe
Transparency Market Research
3
Epigenetics Drugs and Diagnostic Technologies Market
Asia-Pacific RoW
For Sample Report Visit On: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=422
TABLE OF CONTENT
Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology
Chapter 2 Executive Summary 2.1 Market Snapshot: Global Epigenetics Market (2011 & 2018) 2.2 Global Epigenetics Market, by Segments, 2011 (USD Million)
Chapter 3 Market Overview 3.1 Introduction 3.2 Market Drivers
Transparency Market Research
4
Epigenetics Drugs and Diagnostic Technologies Market
3.2.1 Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions 3.2.2 Huge Amounts of Investment 3.2.3 Advances in Screening Tools 3.2.4 Impact Analysis of Market Drivers 3.3 Market Restraints 3.3.1 Genericization of Major Drugs 3.3.2 Impact Analysis of Market Restraints 3.4 Market Opportunities 3.5 Porter’s Five Forces Analysis 3.5.1 Bargaining Power of Buyers 3.5.2 Bargaining Power of Suppliers 3.5.3 Threat of New Entrants 3.5.4 Threat of Substitutes 3.5.5 Competitive Rivalry 3.6 Market Attractiveness Analysis
Chapter 4 Epigenetics Drugs Market, By Mechanism Of Action 4.1 Overview 4.1.1 Global Epigenetic Drugs Market, By Mechanism Of Action, 2010 – 2018 (USD Million) 4.1.2 Histone Deacetylase (HDAC) Inhibitors
Transparency Market Research
5
Epigenetics Drugs and Diagnostic Technologies Market
4.1.3 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million) 4.1.3.1 Vorinostat 4.1.3.2 Global Vorinostat Market, By Types 2010 – 2018 (USD Million) 4.1.3.3 Romidepsin 4.1.3.4 Global Romidepsin Market, By Types 2010 – 2018 (USD Million) 4.1.4 DNA Methyltransferase (DNMT) Inhibitors 4.1.5 Global DNMT Inhibitors Market, By Drugs, 2010–2018 (USD Million) 4.1.5.1 Decitabine 4.1.5.2 Global Decitabine Market, By Types 2010 – 2018 (USD Million) 4.1.5.3 Azacitidine 4.1.5.4 Global Azacitidine Market, By Types 2010 – 2018 (USD Million) 4.1.6 Pipeline Drugs 4.1.6.1 Mocetinostat 4.1.6.2 Abexinostat 4.1.6.3 Resminostat 4.1.6.4 Rocilinostat 4.1.6.5 CHR 3996 4.1.6.6 EVP 0334 4.1.6.7 Panobinostat 4.1.6.8 Belinostat
Transparency Market Research
6
Epigenetics Drugs and Diagnostic Technologies Market
4.1.6.9 Entinostat 4.1.6.10 Valproic Acid 4.1.6.11 Histone Methyltransferase (HMT) Inhibitors
Chapter 5 Epigenetics Diagnostic Technology Market, By Types 5.1 Overview 5.1.1 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD Million) 5.2 DNA Methylation 5.2.1.1 Global DNA Methylation Technology Market, By Types 2010 – 2018 (USD Million) 5.2.2 Chromatin Immunoprecipitation (Chip) 5.2.2.1 Global Chromatin Immunoprecipitation (Chip) Technology Market, By Types 2010 – 2018 (USD Million)
Chapter 6 Global Epigenetics Technologies Market, By Geography 6.1 Overview 6.1.1 Global Epigenetics Technologies Market, By Geography, 2010–2018 (USD Million) 6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %) 6.3 North America
Transparency Market Research
7
Epigenetics Drugs and Diagnostic Technologies Market
6.3.1 North America Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million) 6.4 Europe 6.4.1 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million) 6.5 Asia-Pacific 6.5.1 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million) 6.6 Rest of the World 6.6.1 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million) Chapter 7 Competitive Landscape 7.1 Market Share Analysis, By Key Players (%) Chapter 8 Recommendations 8.1 Market Strategy for Success 8.2 Barriers to be Considered Chapter 9 Company Profiles 9.1 4SC AG 9.1.1 Company Overview 9.1.2 Financial Overview 9.1.3 Product Overview 9.1.4 Business Strategy
Transparency Market Research
8
Epigenetics Drugs and Diagnostic Technologies Market
9.1.5 Recent Developments 9.2 Acetylon Pharmaceuticals, Inc. 9.2.1 Company Overview 9.2.2 Financial Overview 9.2.3 Product Overview 9.2.4 Business Strategy 9.2.5 Recent Developments 9.3 Astex Pharmaceuticals Inc. 9.3.1 Company Overview 9.3.2 Financial Overview 9.3.3 Product Portfolio 9.3.4 Business Strategy 9.3.5 Recent Developments 9.4 Cellcentric Ltd. 9.4.1 Company Overview 9.4.2 Financial Overview 9.4.3 Product Portfolio 9.4.4 Business Strategy 9.4.5 Recent Developments 9.5 Celleron Therapeutics Ltd.
Transparency Market Research
9
Epigenetics Drugs and Diagnostic Technologies Market
9.5.1 Company Overview 9.5.2 Financial Overview 9.5.3 Product Portfolio 9.5.4 Business Strategy 9.6 Celgene Corporation 9.6.1 Business Overview 9.6.2 Financial Overview 9.6.3 Business Strategy 9.6.4 Recent Developments 9.7 Chroma Therapeutics Ltd. 9.7.1 Company Overview 9.7.2 Financial Overview 9.7.3 Product Overview 9.7.4 Business Strategy 9.7.5 Recent Developments 9.8 Epigentek Group Inc. 9.8.1 Business Overview 9.8.2 Financial Overview 9.8.3 Business Strategy 9.8.4 Recent Developments
Transparency Market Research
10
Epigenetics Drugs and Diagnostic Technologies Market
9.9 Eisai Co. Ltd. 9.9.1 Company Overview 9.9.2 Financial Overview 9.9.3 Product Portfolio 9.9.4 Business Strategy 9.9.5 Recent Developments 9.10 Envivo Pharmaceuticals Inc. 9.10.1 Company Overview 9.10.2 Financial Overview 9.10.3 Product Portfolio 9.10.4 Business Strategy 9.11 Epizyme, Inc. 9.11.1 Company Overview 9.11.2 Financial Overview 9.11.3 Product Portfolio 9.11.4 Business Strategy 9.11.5 Recent Developments 9.12 Illumina Inc. 9.12.1 Company Overview 9.12.2 Financial Overview
Transparency Market Research
11
Epigenetics Drugs and Diagnostic Technologies Market
9.12.3 Product Portfolio 9.12.4 Business Strategies 9.12.5 Recent Developments 9.13 Mdxhealth 9.13.1 Company Overview 9.13.2 Financial Overview 9.13.3 Product Portfolio 9.13.4 Business Strategy 9.13.5 Recent Developments 9.14 Merck & Company Inc. 9.14.1 Company Overview 9.14.2 Financial Overview 9.14.3 Product Portfolio 9.14.4 Business Strategy 9.15 Novartis International AG 9.15.1 Company Overview 9.15.2 Financial Overview 9.15.3 Product Portfolio 9.15.4 Business Strategy 9.15.5 Mergers And Acquisitions
Transparency Market Research
12
Epigenetics Drugs and Diagnostic Technologies Market
9.16 Oncolys Biopharma Inc. 9.16.1 Company Overview 9.16.2 Financial Overview 9.16.3 Product Portfolio 9.16.4 Business Strategy 9.17 Pharmacyclics, Inc. 9.17.1 Company Overview 9.17.2 Financial Overview 9.17.3 Product Portfolio 9.17.4 Business Strategy 9.17.5 Recent Developments 9.18 Promega Corporation 9.18.1 Company Overview 9.18.2 Financial Overview 9.18.3 Product Portfolio 9.18.4 Business Strategy 9.18.5 Recent Developments 9.19 Repligen Corporation 9.19.1 Company Overview 9.19.2 Financial Overview
Transparency Market Research
13
Epigenetics Drugs and Diagnostic Technologies Market
9.19.3 Product Portfolio 9.19.4 Business Strategy 9.19.5 Recent Developments 9.20 Spectrum Pharmaceuticals 9.20.1 Company Overview 9.20.2 Financial Overview 9.20.3 Product Portfolio 9.20.4 Business Strategy 9.20.5 Recent Developments 9.21 Syndax Pharmaceuticals, Inc. 9.21.1 Company Overview 9.21.2 Financial Overview 9.21.3 Product Portfolio 9.21.4 Business Strategy 9.21.5 Recent Developments 9.22 Topotarget A/S 9.22.1 Company Overview 9.22.2 Financial Overview 9.22.3 Product Portfolio 9.22.4 Business Strategy
Transparency Market Research
14
Epigenetics Drugs and Diagnostic Technologies Market
9.22.5 Recent Developments 9.23 Valirx Plc 9.23.1 Company Profile 9.23.2 Financial Overview 9.23.3 Product Portfolio And Technology 9.23.4 Business Strategy 9.23.5 Recent Developments
About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Transparency Market Research
15